Patients with B-cell lymphoma receiving anti-CD20 monoclonal antibody-containing chemotherapies and seroreactive patterns in response to COVID-19 vaccination.
作者信息
Inaba Tohru, Okumura Keita, Maekura Chika, Muramatsu Ayako, Kobayashi Tsutomu, Kuroda Junya, Nukui Yoko
机构信息
Department of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Faculty of Clinical Laboratory, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
出版信息
Int J Hematol. 2022 Jun;115(6):913-914. doi: 10.1007/s12185-022-03349-1. Epub 2022 Apr 12.
Abstract
摘要
相似文献
1
Patients with B-cell lymphoma receiving anti-CD20 monoclonal antibody-containing chemotherapies and seroreactive patterns in response to COVID-19 vaccination.
Int J Hematol. 2022 Jun;115(6):913-914. doi: 10.1007/s12185-022-03349-1. Epub 2022 Apr 12.
2
Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment.
Exp Hematol. 2022 Mar;107:20-23. doi: 10.1016/j.exphem.2021.12.396. Epub 2021 Dec 22.
3
The optimal interval before receiving SARS-COV-2 vaccination for patients who have received Anti-CD 20 monoclonal antibodies.
Virulence. 2022 Dec;13(1):2012-2021. doi: 10.1080/21505594.2022.2146380.
4
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies.
Haematologica. 2022 Mar 1;107(3):715-720. doi: 10.3324/haematol.2021.279216.
5
Analysis of vaccine responses after anti-CD20 maintenance in B-cell lymphoma in the Balearic Islands. A single reference center experience.
Front Immunol. 2023 Nov 1;14:1267485. doi: 10.3389/fimmu.2023.1267485. eCollection 2023.
6
Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody.
Int J Hematol. 2022 Jan;115(1):7-10. doi: 10.1007/s12185-021-03247-y. Epub 2022 Jan 4.
7
Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
Front Immunol. 2022 Jan 28;13:834981. doi: 10.3389/fimmu.2022.834981. eCollection 2022.
8
Correction to: Patients with B-cell lymphoma receiving anti-CD20 monoclonal antibody-containing chemotherapies and seroreactive patterns in response to COVID-19 vaccination.
Int J Hematol. 2022 Jun;115(6):916-917. doi: 10.1007/s12185-022-03376-y.
9
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
10
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity.
Blood Cancer Discov. 2022 Mar 1;3(2):95-102. doi: 10.1158/2643-3230.BCD-21-0222.
Zotero 插件